Amarin Corp. (AMRN) Tops Q2 EPS by 11c, Revenues Miss

Amarin Corp. (NASDAQ: AMRN) reported Q2 EPS of $0.04, $0.11 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $135.32 million versus the consensus estimate of $149.48 million.

“The second quarter of 2020 was a challenging but productive quarter for Amarin. Despite headwinds brought on by the adverse patent judgment and the onset of COVID-19 related societal restrictions at the end of the first quarter, the Amarin team continues to be productive with an increasingly positive outlook. We recently resumed a substantial level of in-person interactions with healthcare professionals in various geographies to build on the January launch of VASCEPA for its new and differentiated cardiovascular risk reduction indication. Amarin’s employees are working diligently to succeed driven by our mission to bring the promise of VASCEPA to millions of cardiovascular disease patients in need in the United States and internationally,” stated John F. Thero, president and chief executive officer, Amarin.

For earnings history and earnings-related data on Amarin Corp. (AMRN) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• OmniAb raises 2026 cash guidance on licensing activity
• Greenlane Holdings Inc. (GNLN) reported Q2 result